Your browser doesn't support javascript.
loading
Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals.
Dueñas, Nuria; Navarro, Matilde; Teulé, Àlex; Solanes, Ares; Salinas, Mònica; Iglesias, Sílvia; Munté, Elisabet; Ponce, Jordi; Guardiola, Jordi; Kreisler, Esther; Carballas, Elvira; Cuadrado, Marta; Matias-Guiu, Xavier; de la Ossa, Napoleón; Lop, Joan; Lázaro, Conxi; Capellá, Gabriel; Pineda, Marta; Brunet, Joan.
Afiliação
  • Dueñas N; Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Navarro M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.
  • Teulé À; Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Solanes A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.
  • Salinas M; Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, 089016 Barcelona, Spain.
  • Iglesias S; Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Munté E; Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, 089016 Barcelona, Spain.
  • Ponce J; Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Guardiola J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.
  • Kreisler E; Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Carballas E; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.
  • Cuadrado M; Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Matias-Guiu X; Department of Gynecology, Bellvitge University Hospital, 08908 Hospitalet de Llobregat, 089016 Barcelona, Spain.
  • de la Ossa N; Department of Gastroenterology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Lop J; Department of General Surgery, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Lázaro C; Department of Gynecology, Trias i Pujol University Hospital, Badalona, 089016 Barcelona, Spain.
  • Capellá G; Department of General Surgery, Trias i Pujol University Hospital, Badalona, 089016 Barcelona, Spain.
  • Pineda M; Department of Pathology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Brunet J; Department of Pathology, Trias i Pujol University Hospital, Badalona, 089016 Barcelona, Spain.
Cancers (Basel) ; 12(11)2020 Nov 18.
Article em En | MEDLINE | ID: mdl-33218006
ABSTRACT

BACKGROUND:

Colorectal (CRC) and endometrial cancer (EC) are the most common types of cancer in Lynch syndrome (LS). Risk reducing surgeries (RRS) might impact cancer incidence and mortality. Our objectives were to evaluate cumulative incidences of CRC, gynecological cancer and all-cause mortality after RRS in LS individuals.

METHODS:

Retrospective analysis of 976 LS carriers from a single-institution registry. Primary endpoints were cumulative incidence at 75 years of cancer (metachronous CRC in 425 individuals; EC and ovarian cancer (OC) in 531 individuals) and all-cause mortality cumulative incidence, comparing extended (ES) vs. segmental surgery (SS) in the CRC cohort and risk reducing gynecological surgery (RRGS) vs. surveillance in the gynecological cohort.

RESULTS:

Cumulative incidence at 75 years of metachronous CRC was 12.5% vs. 44.7% (p = 0.04) and all-cause mortality cumulative incidence was 38.6% vs. 55.3% (p = 0.31), for ES and SS, respectively. Cumulative, incidence at 75 years was 11.2% vs. 46.3% for EC (p = 0.001) and 0% vs. 12.7% for OC (p N/A) and all-cause mortality cumulative incidence was 0% vs. 52.7% (p N/A), for RRGS vs. surveillance, respectively.

CONCLUSIONS:

RRS in LS reduces the incidence of metachronous CRC and gynecological neoplasms, also indicating a reduction in all-cause mortality cumulative incidence in females undergoing RRGS.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article